Today: 14 May 2026
Browse Category

Pharmaceuticals 4 December 2025 - 9 December 2025

GSK Stock Near 52-Week Highs: Upgraded 2025 Guidance, Buybacks and Zantac Relief Fuel Re‑Rating

GSK Stock Near 52-Week Highs: Upgraded 2025 Guidance, Buybacks and Zantac Relief Fuel Re‑Rating

GSK shares traded near 52-week highs on December 9, 2025, with London shares at £18.05 and NYSE ADRs at $48.5, both up over 30% year-on-year. The stock surged after a Q3 earnings beat and upgraded 2025 guidance, driven by strong HIV and oncology drug sales. GSK now expects full-year sales growth of 6–7% and core EPS growth of 10–12%.
9 December 2025
···
Eli Lilly (LLY) Stock After Hours on December 8, 2025: China Mounjaro Win, Dividend Hike and What to Watch Before Tuesday’s Open

Eli Lilly (LLY) Stock After Hours on December 8, 2025: China Mounjaro Win, Dividend Hike and What to Watch Before Tuesday’s Open

Eli Lilly shares closed at $998 on December 8, down 1.3%, marking a seventh straight decline and leaving the stock about 10% below its recent high. The company reported a 15% dividend increase, secured Chinese reimbursement for Mounjaro, and saw Nobel laureate Carolyn Bertozzi return to its board. Competition and price cuts in weight-loss drugs weighed on the stock.
9 December 2025
······
Pfizer (PFE) Stock Today: Hemophilia Breakthrough, Metsera Deal and AI Cost Cuts – Price, Forecast and News for December 8, 2025

Pfizer (PFE) Stock Today: Hemophilia Breakthrough, Metsera Deal and AI Cost Cuts – Price, Forecast and News for December 8, 2025

Pfizer shares traded near $26 on December 8, 2025, with a market cap around $148 billion and a dividend yield of 6.6–7%. The stock remains down about 36% over five years and over 50% below its December 2021 peak. New Phase 3 hemophilia data, an obesity-drug acquisition, and AI-driven cost cuts drew investor attention. Year-to-date total return is flat to slightly positive, depending on dividend inclusion.
8 December 2025
···
Nurix Therapeutics (NRIX) Stock Soars on ASH 2025 Trial Data: Latest News, Analyst Forecasts and Outlook as of December 8, 2025

Nurix Therapeutics (NRIX) Stock Soars on ASH 2025 Trial Data: Latest News, Analyst Forecasts and Outlook as of December 8, 2025

Nurix Therapeutics shares jumped about 20% to $21.70 intraday on December 8, 2025, after new Phase 1 data for its BTK degrader bexobrutideg (NX-5948) in blood cancers was presented at the ASH Annual Meeting. The company reported an 83% response rate in relapsed/refractory CLL/SLL patients and scheduled a webcast for the evening. Volume was well above normal, with shares trading near a 52-week high.
8 December 2025
··
Johnson & Johnson (JNJ) Stock Outlook 2026: Talc Verdicts, Stelara Cliff and a 40% Rally – What Investors Need to Know Now

Johnson & Johnson (JNJ) Stock Outlook 2026: Talc Verdicts, Stelara Cliff and a 40% Rally – What Investors Need to Know Now

Johnson & Johnson shares traded at $202.48 on December 8, 2025, near a 52-week high and up nearly 35% over the past year. The company raised its 2025 sales guidance to $93–94 billion and EPS to about $10.80–$10.90 after beating Q2 and Q3 expectations. Analysts’ 12-month targets average just above the current price, with a consensus “Buy” rating. J&J faces Stelara patent loss, talc lawsuits, and MedTech pricing pressure in China.
8 December 2025
··
Recursion Pharmaceuticals (RXRX) Stock Jumps on Positive FAP Trial Data: Latest News, AI Drug Discovery Outlook and Analyst Forecasts

Recursion Pharmaceuticals (RXRX) Stock Jumps on Positive FAP Trial Data: Latest News, AI Drug Discovery Outlook and Analyst Forecasts

Recursion Pharmaceuticals reported Phase 1b/2 trial data showing its AI-discovered drug REC-4881 reduced polyp burden by a median 43% at 13 weeks in patients with familial adenomatous polyposis. Shares rose as much as 6% pre-market before settling in the mid-$4 range. Most patients maintained or improved reductions after stopping treatment. No approved drugs currently exist for this condition.
8 December 2025
···
Merck Stock (MRK) Before the Bell on December 8, 2025: Keytruda Setback, $8B Bond Deal and What Investors Should Watch

Merck Stock (MRK) Before the Bell on December 8, 2025: Keytruda Setback, $8B Bond Deal and What Investors Should Watch

Merck shares closed at $99.72 on Friday, down 1.16%, with volume above average. The stock sits about 6% below its November 52-week high and trades at roughly 13 times trailing earnings, with a dividend yield of 3.3–3.5%. A German court blocked Merck’s launch of subcutaneous Keytruda, citing patent infringement claims by Halozyme.
8 December 2025
··
Eli Lilly (LLY) Stock: Key Catalysts to Watch Before the Market Opens on December 8, 2025

Eli Lilly (LLY) Stock: Key Catalysts to Watch Before the Market Opens on December 8, 2025

Eli Lilly shares closed Friday at $1,010.31, down 0.41%, before edging higher after hours. The stock sits about 9% below its late-November record high. Over the weekend, China added Lilly’s Alzheimer’s drug Kisunla to a new insurance list for high-priced therapies, offering improved market access with smaller price cuts than usual. Investors await Monday’s session for reaction.
7 December 2025
··
Vertex Pharmaceuticals (VRTX) Stock on December 7, 2025: Casgevy Breakthrough, Pain-Drug Setbacks and What 2026 Forecasts Are Saying

Vertex Pharmaceuticals (VRTX) Stock on December 7, 2025: Casgevy Breakthrough, Pain-Drug Setbacks and What 2026 Forecasts Are Saying

Vertex Pharmaceuticals shares closed at $455.48 on December 5, 2025, valuing the company at about $115–116 billion. New data presented December 6 showed CASGEVY gene therapy achieved 12-month crisis- and transfusion-free outcomes in children 5–11 with sickle cell disease and beta thalassemia, though one pediatric patient died from transplant complications. Vertex plans global regulatory filings for this age group in early 2026.
7 December 2025
····
Merck (MRK) Stock Outlook on December 7, 2025: Price Action, Keytruda Setback, Debt Deal and 2026 Analyst Forecasts

Merck (MRK) Stock Outlook on December 7, 2025: Price Action, Keytruda Setback, Debt Deal and 2026 Analyst Forecasts

Merck closed an $8 billion senior notes offering, likely to help fund its $9.2 billion Cidara Therapeutics acquisition. The company also reported new regulatory wins and raised its dividend, but faced a patent setback for subcutaneous Keytruda in Germany. Merck shares ended December 5 at $99.72, down 1.2%, and remain near the top of their 52-week range. Trading volume was above average.
7 December 2025
···
Novo Nordisk Stock (NVO) in December 2025: Alzheimer’s Failure, GLP‑1 Price Cuts and 2026 Turnaround Hopes

Novo Nordisk Stock (NVO) in December 2025: Alzheimer’s Failure, GLP‑1 Price Cuts and 2026 Turnaround Hopes

Novo Nordisk shares have dropped about 45% in 2025 and over 50% from their 2024 peak, following profit warnings, slower GLP-1 growth, and a failed Alzheimer’s trial. The stock now trades near $47.9, down sharply after the EVOKE and EVOKE+ studies showed no significant benefit for semaglutide in early Alzheimer’s. Revenue in Q3 2025 rose 5% to DKK 74.98 billion, missing analyst expectations.
7 December 2025
··
Eli Lilly (LLY) Stock on 6 December 2025: Zepbound Price Cuts, $1 Trillion Milestone and 2026 Forecasts

Eli Lilly (LLY) Stock on 6 December 2025: Zepbound Price Cuts, $1 Trillion Milestone and 2026 Forecasts

Eli Lilly shares traded near $1,010 on December 6, 2025, with a market value just under $1 trillion after a brief pullback from record highs. The company cut list prices on Zepbound vials this week, pressuring margins and sending the stock lower. Zepbound and Mounjaro generated $10.1 billion in Q3 sales, making Lilly’s GLP-1 drugs the world’s top-selling franchise. Most analysts maintain Buy ratings, with 12-month targets around $1,060–$1,090.
6 December 2025
···
Johnson & Johnson Stock Today (JNJ): Price, Talc Verdicts, New Bladder Cancer Data and 2026 Outlook – December 6, 2025

Johnson & Johnson Stock Today (JNJ): Price, Talc Verdicts, New Bladder Cancer Data and 2026 Outlook – December 6, 2025

Johnson & Johnson shares closed at $201.90 on December 5, 2025, less than 3% below their 52-week high. The stock has climbed about 35% over the past year, fueled by earnings beats, acquisitions, and new clinical data. The company faces large talc litigation verdicts and plans to spin off its orthopaedics unit. Market capitalization stands near $485 billion.
6 December 2025
··
Gilead Sciences Stock (GILD) Outlook 2026: Latest News, Trodelvy Data, Dividend and Analyst Forecasts

Gilead Sciences Stock (GILD) Outlook 2026: Latest News, Trodelvy Data, Dividend and Analyst Forecasts

Gilead Sciences shares closed at $121.22 on December 5, 2025, about 6% below their 52-week high. Third-quarter revenue rose 3% year-over-year to $7.8 billion, with HIV product sales up 4% to $5.3 billion. Veklury sales dropped as COVID cases fell. The company continues to invest in oncology and cell therapy despite near-term earnings pressure.
6 December 2025
···
Eli Lilly (LLY) Stock Outlook: Can the Obesity-Drug Giant Keep Justifying a $1,000 Share Price?

Eli Lilly (LLY) Stock Outlook: Can the Obesity-Drug Giant Keep Justifying a $1,000 Share Price?

Eli Lilly shares traded above $1,000 on December 5, 2025, after recently crossing a $1 trillion market cap, the first for a healthcare company. The stock is up over 30% year to date despite an 8% pullback in the past week. Lilly is cutting prices on its obesity drug Zepbound and preparing to seek accelerated approval for a new weight-loss pill. The company’s dividend yield remains around 0.6%.
5 December 2025
··
GSK plc Stock in December 2025: Buybacks, New CEO and Strong Q3 Results Drive a 40% Rally

GSK plc Stock in December 2025: Buybacks, New CEO and Strong Q3 Results Drive a 40% Rally

GSK shares traded near multi-year highs on 4 December, closing at 1,826–1,837p in London and $48.57 in New York, up over 40% year-to-date. The company repurchased more than 11.5 million shares since late September as part of a £2 billion buyback. New executive share options were granted on 5 December. Market cap stands at about £73 billion in London and just under $100 billion in New York.
5 December 2025
··
Amgen (AMGN) Stock Near Record Highs on Obesity Drug Hopes – Is It Still a Buy in December 2025?

Amgen (AMGN) Stock Near Record Highs on Obesity Drug Hopes – Is It Still a Buy in December 2025?

Amgen traded near $343 Thursday, close to record highs after a year of strong earnings and FDA approval for its lung-cancer drug Imdelltra. Shares are up about 34% year-to-date, outpacing the broader market. Trefis set a bullish $450 target, citing 12% revenue growth and $13 billion in free cash flow. EverSource Wealth Advisors cut its Amgen stake by nearly 28% in Q2.
4 December 2025
··
Regeneron (REGN) Price Target Hits $1,057 as BMO and Canaccord Lift Forecasts on Dupixent Growth

Regeneron (REGN) Price Target Hits $1,057 as BMO and Canaccord Lift Forecasts on Dupixent Growth

BMO Capital raised its Regeneron price target to $850, citing Dupixent momentum and improved Eylea HD trends. Canaccord Genuity set a Street-high target of $1,057, expecting Dupixent growth to offset Eylea declines. Regeneron now holds a “Moderate Buy” consensus from 28 analysts, with an average target near $768. The stock has surged over 50% in six months amid active institutional trading.
4 December 2025
·
Tonix Pharmaceuticals (TNXP) Stock Today, December 4, 2025: Tonmya Launch, Buyback and $400M ATM Define a Volatile Biotech Story

Tonix Pharmaceuticals (TNXP) Stock Today, December 4, 2025: Tonmya Launch, Buyback and $400M ATM Define a Volatile Biotech Story

Tonix Pharmaceuticals’ stock (NASDAQ: TNXP) closed near $19.98 on December 4, 2025, up roughly 10–12% for the day and about 10,515% over the past year. The surge follows FDA approval and U.S. launch of Tonmya, the first new fibromyalgia drug in over 15 years. Market cap stands near $190 million. Investors remain focused on whether Tonmya sales can offset heavy cash burn and potential dilution.
4 December 2025
··
1 … 29 30 31 32 33 … 40

Stock Market Today

  • NVIDIA Stock Rises 2.29% with Strong Technical Indicators but Volume Divergence Signals Caution
    May 13, 2026, 10:42 PM EDT. NVIDIA's stock price increased 2.29% on May 13, 2026, continuing a six-day winning streak and rising 7.92% over two weeks. Notably, the stock broke a strong short-term trend line at $223.03, suggesting further gains toward the $264.30 resistance level. Moving averages signal a buy, with the short-term trend above the long-term. However, declining volume despite rising prices may indicate a potential reversal. Support levels are identified at $213.87, $195.72, and $184.89, with sell signals triggered if these break. Technical caution is advised due to a sell signal from the 3-month MACD indicator and volume-price divergence. Market watchers should monitor NVIDIA closely for short-term shifts amid medium risk trading conditions.

Latest articles

Enovix Stock Drops After Q1 Beat as Smartphone Battery Tests Stay Unfinished

Enovix Stock Drops After Q1 Beat as Smartphone Battery Tests Stay Unfinished

14 May 2026
Enovix shares dropped 12.9% to $6.35 after hours Wednesday despite beating first-quarter revenue and adjusted-loss estimates. The decline followed news that smartphone battery qualification remains unfinished, with the company passing 72 of 75 customer tests. Revenue rose 49% to $7.6 million. Enovix cited progress in defense, industrial, and smart-eyewear sales.
Lightwave Logic Stock Jumps as AI-Photonics Bet Heads for a 2027 Production Test

Lightwave Logic Stock Jumps as AI-Photonics Bet Heads for a 2027 Production Test

14 May 2026
Lightwave Logic reported Q1 revenue up 27% to $29,000 and a net loss widening to $6.3 million. Shares rose 14% after the company said it is negotiating a supply and licensing deal for high-volume production in 2027. Four Fortune 500 customers are now in Stage 3 prototyping. Cash and equivalents totaled about $100 million as of May 11.
USA Rare Earth Stock Watch: Q1 Revenue, $1.75 Billion Cash and the China Supply Crunch

USA Rare Earth Stock Watch: Q1 Revenue, $1.75 Billion Cash and the China Supply Crunch

14 May 2026
USA Rare Earth reported Q1 revenue of $5.7 million and a net loss of $67 million, ending March with $1.75 billion in cash after a $1.5 billion PIPE. The company expects to sign documents this month for $1.6 billion in U.S. Commerce Department funding. Texas awarded a $14.18 million grant for the Round Top project. USA Rare Earth agreed in April to acquire Brazil’s Serra Verde for $2.8 billion.
Go toTop